We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

COVID-19 Molecular Gene Test Uses Nanosensor Technology to Detect Early and Asymptomatic Infections

By LabMedica International staff writers
Posted on 01 Feb 2022
Print article
Image: Check4 (Photo courtesy of IdentifySensors Biologics)
Image: Check4 (Photo courtesy of IdentifySensors Biologics)

A molecular gene test based on innovative nanosensor technology could reshape the future of COVID-19 diagnostic testing.

IdentifySensors Biologics (Shaker Heights, OH, USA), along with researchers at Purdue University (West Lafayette, IN, USA), has developed the new digital technology that aims to replace 50-year PCR testing for multiple infections, including COVID variants. It has finalized proof-of-concept research for its all-new COVID-19 testing method. IdentifySensors is currently in the commercialization stage with Check4, its testing platform that comprises two parts - a re-useable reader and cartridges that intend to check for several infections and pathogens. The first cartridges are intended to test for COVID and the multiple variants, and then a multiplex cartridge which will test for COVID and influenza A and B.

Check4 intends to be a highly accurate, over-the-counter self-test that is fast, accurate, and affordable. It detects early and asymptomatic infections with the accuracy of a PCR test, but without all the necessary reagents, machines, people, and delays. It is intended to avoid the limitations of current molecular tests such as enzymatic reactions, amplification, sample preservation or sample transportation, which can introduce artifacts and raise the risk of false positives. It is not an inaccurate antigen test. This electronic-based disruptive technology intends to use newly-developed nanosensors, saliva, and a user’s smartphone to disrupt the way testing is done now, and into the future. Using saliva and the user’s smartphone, results will be delivered within minutes. Check4 is easy to use and fast, accurate, and affordable. Future intended tests include MRSA, Lyme, Hep C and B, foodborne pathogens, and more.

“With COVID still raging around the globe, our test is a game-changer,” said Dr. Gregory Hummer, founder of IdentifySensors Biologics. “It’s fast, affordable and intends to provide accurate results withing minutes on your smartphone. Check4 can help us get back to living a more normal life.”

Related Links:
IdentifySensors Biologics 
Purdue University

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.